Short answer
Exelixis Inc (EXEL) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Exelixis reported financial results for the quarter ended October 2, 2026.
Exelixis Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exelixis reported financial results for the quarter ended October 2, 2026
- Corporate update included in Exhibit 99.1, the key source for detailed results and guidance
- Disclosure furnished under Item 2.02, limiting direct liability and incorporation into other SEC filings
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $658.7M vs $597.8M, driven by cabozantinib product revenue of $604.9M
- GAAP diluted EPS $0.85 vs $0.69, supported by 8.2% lower diluted shares from repurchases
- FY2026 revenue guidance unchanged at $2.500B-$2.550B, while effective tax-rate guidance improved to 16%-18%
- Zanzalintinib CRC FDA decision now targeted for March 3, 2027 after a three-month review extension
- $402.1M of the authorized $750M buyback completed, with $54.03 average repurchase price
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Exelixis Inc 8-K filings
Get the next EXEL 8-K as it lands
Follow EXEL for push alerts, or ask the research agent what this filing means.